Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
ap6mJHf1sa1TSZnh
Listen
